News

May 18, 2026

John Hess Sells $36M CVX in One Day Post-Merger

John Hess, now a Chevron director after the 2025 merger, sold 195,000 CVX shares for $36M on May 6, 2026 at $183.90-$185.21. His combined trust and direct holdings still total over 1.18M Chevron shares.

Marc Benioff's CRM Distributions: Inside the 10b5-1 Cadence

Through Q1 2026 the Salesforce CEO continued mechanical 10b5-1 exercise-and-sell activity while retaining 11.9M shares via trusts and derivatives. The pattern reads as compensation conversion, not conviction shift.

Morningstar Founder Mansueto Sells $6.1M MORN Under 10b5-1

Morningstar founder Joe Mansueto sold roughly $6.1M of MORN across May 5-15 under a 10b5-1 plan adopted November 2025. He still beneficially owns 37.5% of the company.

Charles Schwab Sells $22M of SCHW in 7 Trading Days

The Schwab founder sold roughly $22M of SCHW across April 23-May 1 at prices from $90 to $91.86. He remains a 10% beneficial owner with 54.4M directly-held Class A shares plus 56.1M via family trusts.

Publicis Buys LiveRamp at $38.50: RAMP Holder File Read

Publicis is paying $38.50 per share in cash for LiveRamp, a 29.8% premium. With 288 institutional holders and a year-end close, the ownership file is now a merger-arb problem, not a fundamental one.

NextEra to Buy Dominion for $67B: NEE Holder Stack Read

NextEra is paying $67B in stock for Dominion at a fixed 0.8138 exchange ratio. The combined book stretches across NEE's 3,166 holders and D's institutional roster — here is who is set up to gain and who has to swap exposure.

Regeneron Fianlimab Trial Fails: What 1,455 REGN Holders Now See

Regeneron's fianlimab+Libtayo combo missed its primary PFS endpoint vs Keytruda at p=0.0627. The data angle is in who has to defend the position — and who already trimmed.

May 17, 2026

May 17News

Gates Foundation Trust Sells Last $3.7B of Microsoft in Q1

The Gates Foundation Trust's Q1 2026 13F-HR, filed May 15, shows zero Microsoft shares — ending a position that one quarter earlier was worth $3.7B and made up 10.5% of the portfolio. The foundation is now a four-name industrial stack led by Berkshire and Waste Management.

May 16, 2026

Roku Founder Wood Sells $9.7M at $128-131

Roku founder and CEO Anthony Wood sold 75,000 Class A shares worth $9.7M on May 11, 2026 at prices from $128-131 per share under a prearranged 10b5-1 plan, while retaining 16.2 million Class B shares. FMR LLC holds 10.5% of the company.

CrowdStrike CEO Sells at $560 Under 10b5-1 Plan

CrowdStrike CEO George Kurtz sold CRWD shares at $557-565 on May 14, 2026 under a Rule 10b5-1 prearranged plan — the latest in a multi-year pattern of programmatic selling at what are now post-outage recovery highs. Institutional investors Jennison Associates and Citadel remain large holders.

Starbucks Cuts 300 Jobs as Capital Group Holds $18B

Starbucks is cutting 300 corporate jobs under CEO Brian Niccol's turnaround plan. Despite the restructuring pain, Capital Group entities hold $18.43B in SBUX — ranking as the top two active institutional owners. Here's what the holder table reveals about conviction through the reset.

Nvidia Earnings Approach: 6,105 Holders, Goldman at $38B

As Nvidia approaches its Q1 FY2027 earnings report, analysts are resetting price targets. 13F Insight data shows 6,105 institutional holders with Goldman Sachs at $38.47B and Capital Research at $33.66B among the active-manager conviction plays.

Berkshire Tripled Alphabet, Entered Delta in Q1 2026

Warren Buffett's Berkshire Hathaway disclosed a tripled stake in Alphabet and a fresh position in Delta Air Lines in its Q1 2026 13F. Here's what 13F Insight's institutional ownership data reveals about the broader conviction picture around GOOG and DAL.

May 15, 2026

Corning: Capital Research $3B Bet on AI Fiber-Optic Glass

AI infrastructure capex headlines extend institutional attention to optical-fiber and specialty-glass franchises. Corning carries Capital Research Global Investors at $2.97 billion — concentrated active conviction on AI fiber-optic infrastructure plus diversified specialty-glass franchise economics.

Biogen: Primecap $2.7B Concentrated Active Bet Pre-Trial

Alzheimer trial results focus institutional attention on Biogen. Primecap Management holds $2.71 billion in BIIB — the largest concentrated active manager position and second-largest institutional holder overall. A distinctive long-cycle conviction bet on neurodegenerative pipeline.

Texas Instruments: JPMorgan 0.46% Analog-Semi Overweight

Cisco AI restructuring headlines focus institutional attention on the semiconductor cycle. Texas Instruments — the largest US analog-semiconductor manufacturer — carries JPMorgan Chase at $1.8 billion and 0.46% portfolio weight. A modest active overweight on the multi-decade analog franchise.

Abbott Labs: Capital Research 0.79% MedTech Bet

AI cybersecurity headlines push capital flow scrutiny across all sectors. Abbott Laboratories — the diversified medical-devices, diagnostics, nutrition, and pharma franchise — carries Capital Research Global Investors at $4.07 billion and 0.79% portfolio weight. A medtech-quality concentration thesis.

Hormuz Cycle: EOG Resources Holders Led by Capital World 1.02%

The Strait of Hormuz tape extends US shale-and-energy exposure. EOG Resources — one of the largest US independent shale producers — carries Capital World Investors at $7.50 billion and 1.02% portfolio weight. The cleanest single-fund active conviction on the US shale franchise economics.

KKR Holder Read: Capital International 0.76% + Wellington 0.60%

KKR has transformed from a private-equity firm into a diversified alternative-asset platform with public-equity listed shares. The 13F holder book reveals concentrated active conviction at multiple large diversified managers — Capital International at 0.76% portfolio, Wellington at 0.60%, Fidelity at moderate weights.